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1  | INTRODUCTION
Obesity and the consumption of a high‐fat diet significantly in‐
crease the levels of free fatty acids (FAs) in plasma, as well as the 
susceptibility to chronic inflammatory processes.1 Being over‐
weight, as a consequence, represents a common pathophysiolog‐
ical basis for many pathologies, including chronic degenerative 
diseases, and this constitutes one of the most important current 
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Abstract
The high concentrations of free fatty acids as a consequence of obesity and being 
overweight have become risk factors for the development of different diseases, 
including neurodegenerative ailments. Free fatty acids are strongly related to in‐
flammatory events, causing cellular and tissue alterations in the brain, including cell 
death, deficits in neurogenesis and gliogenesis, and cognitive decline. It has been 
reported that people with a high body mass index have a higher risk of suffering from 
Alzheimer's disease. Hormones such as oestradiol not only have beneficial effects on 
brain tissue, but also exert some adverse effects on peripheral tissues, including the 
ovary and breast. For this reason, some studies have evaluated the protective effect 
of oestrogen receptor (ER) agonists with more specific tissue activities, such as the 
neuroactive steroid tibolone. Activation of ERs positively affects the expression of 
pro‐survival factors and cell signalling pathways, thus promoting cell survival. This 
review aims to discuss the relationship between lipotoxicity and the development of 
neurodegenerative diseases. We also elaborate on the cellular and molecular mecha‐
nisms involved in neuroprotection induced by oestrogens.
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public health problems.2 A diet rich in simple sugars and saturated 
FAs reduces the expression of brain‐derived neurotrophic factor 
(BDNF) and low BDNF levels are associated with insulin resistance 
and metabolic syndrome.3 The fat ingested with food has a dual 
function in the body. First, the energetic function of ingested fat 
is associated with the regulation of gene expression that affects 
the metabolism of lipids, carbohydrates and proteins, as well as 
cell growth and differentiation.4 Second, FAs interact with the 
genome via different mechanisms, including: (i) alteration of var‐
ious transcription factors such as proliferator‐activated receptor, 
insulin and liver X receptor, hepatocyte nuclear factor 4, nuclear 
factor‐kappa B (NF‐κB) and sterol regulatory element‐binding pro‐
teins; (ii) regulation of enzymes such as cyclooxygenase, protein 
kinase C, superoxide dismutase and catalase; and (iii) changes in 
the structure of cell membrane, affecting G protein‐coupled or ty‐
rosine kinase receptors.5
Metabolic alterations modify the correct functioning of the cen‐
tral nervous system (CNS) by changing the neuronal and glial envi‐
ronment.6 Also, the progression of CNS diseases is a consequence 
of the occurrence of exacerbated inflammatory processes that lead 
to continuous and systematic deterioration of brain tissues.7 Recent 
studies have suggested that people with obesity are more prone 
to develop cognitive pathologies such as Alzheimer's disease (AD), 
amongst others,8 leading to the generation of a large number of in‐
flammatory processes as a consequence of the excess of free FAs.9‐11
Some decades ago, it was possible to characterise the cellular 
components responsible for the regulation and control of inflam‐
mation in the nervous system.12 The glial component primar‐
ily comprises astrocytes and microglia, which are the main cells 
that are responsible for the regulation of inflammation.13 Acute 
activation of glia modulates the neuroinflammatory response in 
a protective manner. By contrast, chronic glial activation pro‐
motes neurodegeneration via the secretion of inflammatory fac‐
tors involved in neuronal loss.14 The regulatory mechanism is an 
extremely complex process determined by the transduction of 
inflammatory‐type signals mediated by cytokines and chemok‐
ines.15 Despite the large body of information available concerning 
the inflammatory mechanisms, it is not yet completely clear how 
the regulation of inflammation is carried out and how it can be al‐
tered in pathological events.16 However, previous studies support 
the idea that modulation of exacerbated inflammatory processes 
may hold therapeutic potential for many diseases of the nervous 
system. Inflammation can be regulated by the elimination and de‐
toxification of neurotransmitters such as glutamate and intracel‐
lular messengers by the glial cells. These cells are able to regulate 
glutamate levels under physiological and pathological conditions, 
contributing to oxidative stress reduction, synaptic homeostatic 
maintenance and the regulation of inflammatory signals.17,18 In 
this regard, neuroactive steroids could play a critical role in the 
regulation of inflammatory processes in a pathological context, 
mainly by affecting the immunomodulatory function of astrocytes 
and microglia. Oestrogens can positively regulate the expression 
of inflammatory mediators (cytokines and chemokines) produced 
by microglia and other glial cells that are involved in neuroinflam‐
mation and neurodegeneration.19
It is clear that the brain is a steroidogenic tissue20 and a target 
of endogenous and exogenous steroids. It is noteworthy that neuro‐
active steroids are steroids that originate from peripheral glands (ie, 
steroid hormones), which have effects on nervous tissue, whereas 
neurosteroids are those directly synthesised in the nervous system. 
It has been reported that treatment with oestradiol regulates the 
expression of endoplasmic reticulum stress proteins,11,21,22 protects 
mitochondria,22‐25 and regulates the expression and activation of 
membrane oestrogen receptors (ERs), in addition to reducing the 
activity of proapoptotic proteases such as calpain and caspase‐3 in 
glial cells under different metabolic challenges.26 Although palmitic 
acid may induce toxicity in glial cells27,28 and oestrogenic compounds 
attenuate palmitic acid‐induced neuroinflammation,29‐32 the signal‐
ling mechanisms involved in these oestrogenic actions are not fully 
explored and deserve further studies. This review highlights the 
inflammatory processes evoked by free FAs in glial cells. We also 
discuss the mechanisms of action of neuroactive steroids in the reg‐
ulation of inflammation in glial cells, as well as the therapeutic op‐
tions that attenuate degeneration in the nervous system caused by 
glial reactivity.
2  | METABOLISM OF FATTY ACIDS AND 
CELLULAR MECHANISMS DURING INJURY
FAs are an essential source of energy and ATP for the maintenance 
of cellular functions.33 Excess FAs, glucose and other nutrients can 
be efficiently stored as adipose tissue.34 Triglycerides provide more 
than twice the energy in the form of ATP compared to carbohydrates 
or proteins35 because their catabolism generates more reducing 
equivalents (FADH2 and NADH2) and acetyl‐CoA during β‐oxidation 
in the mitochondria.
FAs are fundamental for cellular functioning because they are 
used as energy sources via β‐oxidation under strict enzymatic control 
at the mitochondrial and peroxisomal levels.36 It has been reported 
that FAs can be cytotoxic when the regulation of their metabolism is 
not adequate, with characteristic physiopathological consequences 
such as the induction of damage in various organs (eg, liver) that 
can culminate in non‐alcoholic fatty liver disease, non‐alcoholic ste‐
atohepatitis, liver cirrhosis and hepatocellular carcinoma.37 At the 
pancreatic level, FA‐associated toxicity may lead to dysfunction of β 
cells. At the cardiac level, it may lead to the loss of myocardial con‐
tractility with consequent heart failure, whereas it may act as a pre‐
cursor of neuroinflammatory processes in the brain.38
Lipotoxicity is a phenomenon characterised by increased levels 
of FAs. Also, increased amounts of FAs can induce the activation 
of various metabolic pathways that cause the uncoupling of cellu‐
lar metabolism, with the generation of signalling cascades related 
to the start of programmed cell death and finally cellular energetic 
failure.39 In obesity, excessive consumption of foods rich in carbohy‐
drates and excessive release of FAs by adipose tissue both exceed 
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the storage limit and the capacity of oxidation in different tissues.40 
In this regard, FAs are redirected to harmful non‐oxidative metabolic 
pathways, which are linked with the intracellular accumulation of 
toxic metabolites such as reactive oxygen species (ROS).41
The oxidation of FAs increases the proportion of acetyl coen‐
zyme A/coenzyme A and NADH/NAD+ in mitochondria, which re‐
sults in the inactivation of pyruvate dehydrogenase.42 Inactivation 
of this enzyme leads to the accumulation of citrate and subsequent 
inactivation of the enzyme phosphofructokinase. In turn, this lat‐
ter inactivation leads to the accumulation of glucose 6‐phosphate, 
which then stimulates the synthesis of glycogen and the inhibition of 
hexokinase, resulting in the inhibition of glucose uptake.43
Large amounts of FAs available at the cellular level that are not 
used by cellular activity can negatively alter the process of β‐oxida‐
tion and affect cell/energy balance. When this process is impaired, 
the FAs are metabolised by alternative routes and are degraded or 
incorporated into other molecules.44 FAs can have damaging cellular 
effects by increasing the activity of the serine palmitoyl transferase 
that catalyses the condensation of palmitoyl coenzyme A and serine 
to form dihydrosphingosine. This is the first step for the de novo 
synthesis of ceramide, a molecule involved in the regulation of cellu‐
lar processes such as cellular differentiation and proliferation, in ad‐
dition to cellular apoptosis, via the expression of the anti‐apoptotic 
molecule Bcl2.45 The accumulation of metabolites involved in the 
synthesis of ceramides, along with other catabolic products of Fas, 
triggers a signalling network between the endoplasmic reticulum, 
the cell nucleus and the mitochondria. For example, FA alters im‐
portant apoptotic factors of the endoplasmic reticulum such as ino‐
sitol 1 recruiting protein (IRE1), transcription activating factor 6 and 
protein kinases such as the protein kinase R of the endoplasmic re‐
ticulum (PERK).46 The intracellular accumulation of palmitic acid and 
stearic acid causes the activation of apoptosis via IRE1 and PERK in 
humans with non‐alcoholic steatohepatitis.47 The mitochondria are 
the main cellular compartment affected by FAs, where an increase 
in mitochondrial β‐oxidation, induction of cytochrome P450 and leu‐
kocyte infiltration result in the generation of oxidative stress and ni‐
trogen‐free radicals.48 Several studies on obesity and non‐alcoholic 
steatohepatitis in male patients have revealed an increase in the ex‐
pression of metabolites derived from oxidative stress caused by the 
excess of FAs.49 Some of these metabolites include 4‐nitrotyrosine, 
F I G U R E  1   Fatty acids (FAs) induce inflammation in the nervous system and attenuate the signalling pathway of insulin in obesity. The 
excess of FAs produce inflammation principally by means of three mechanisms. Increase in lipotoxicity when the FA concentration exceeds 
the oxidative requirements, increasing the levels of diacylglycerol (DAG) and ceramide. DAG activates protein kinase C (PKC), which 
activates the nuclear factor inhibitor NF‐kB (IkB) kinase (IKKβ‐NF‐kB) pathway, causing inflammation. A high concentration of ceramides 
activates the nodule‐type receptor that contains a purine domain (NLRP3), modulating the release of interleukin (IL)‐1β and also leads to the 
activation of the protein phosphatase 2A (PP2A), attenuating the signalling pathway of insulin. Palmitic acid dysregulates the function of 
the	endoplasmic	reticulum	(ER)	producing	stress	and	inflammation	via	NF‐kB,	N‐terminal	c‐Jun	(JNK)	and	NLRP3	inflammasome,	leading	to	
further generation of reactive oxygen species (ROS) in mitochondria. Palmitic acid activates the toll‐like receptor (TLR)‐4 through fetuin A; 
likewise, high‐fat diets increase lipopolysaccharide levels, an activator of this receptor, which leads to an increase in the activity of the IKKβ‐
NF‐kB pathway. BBB, blood brain‐barrier; PI3K, phosphoinositide 3‐kinase; TNF, tumour necrosis factor
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hydroxynonenal, substances reactive to thiobarbituric acid (lipoper‐
oxidation markers) and 8‐hydroxydeoxyguanosine (a marker of DNA 
damage), amongst other biomarkers of oxidative stress.50
Several studies have shown that toll‐like receptors (TLRs), which 
are responsible for transducing FA‐induced signalling, recognise 
the pathogens and respond by activating the innate immune re‐
sponse.51,52 In macrophage cultures of female C57BL/6 mice, lauric 
acid could activate TLR4 receptor and dimerise with TLR2.53 TLR4 
can also be activated by palmitic acid, thereby triggering the trans‐
location to the nucleus of NF‐κB and subsequent overexpression of 
the pro‐inflammatory cytokines tumour necrosis factor (TNF)α and 
interleukin (IL)‐6.54 These cytokines, in turn, contribute to the in‐
flammatory process associated with obesity55 (Figure 1).
Previous studies have reported an association between high‐
fat diets and cognitive decline in humans.56 In addition, a higher 
probability of suffering from dementia has been associated with 
the development of inflammatory processes and obesity.22 A sed‐
entary lifestyle, a lack of physical activity and unhealthy eating 
habits have been catalogued as determining factors in the devel‐
opment of neurodegenerative diseases as a resukt of the inflam‐
matory response that is generated in the brain.57 Furthermore, 
these factors may influence the outcome of other types of inju‐
ries that alter brain function, such as traumatic brain injury (TBI), 
thereby producing alterations in the cerebral energy machinery 
that prevent tissue repair and delay the recovery of cerebral func‐
tion.58 Indeed, obesity, characterised by insulin resistance and the 
presence of neuroinflammatory processes, increases the conse‐
quences of TBI.59 This occurs because of the transient alteration 
of glucose demands and the presence of high concentrations of 
free FAs characteristic of obese patients.60
Some studies have reported an increase in the levels of saturated 
FAs in post‐mortem human brains with TBI.61,62 In studies of male 
and female mice that underwent TBI, obesity was found to increase 
the activation of glial cells (astrocytes and microglia), the expression 
of neuroinflammatory factors, and the impairment of learning and 
memory processes.63 All of these alterations suggest that obese 
people have a reduced ability of the injured brain to respond with 
neuroprotective and anti‐inflammatory actions. Therefore, obesity 
can be a contributing factor triggering neuroinflammation.64 Also, 
it has been well established that oestrogens play an essential role in 
the prevention of body weight gain.65 There is a strong relationship 
between the development of obesity, diabetes and the metabolic 
syndrome, with a dramatic drop in the circulating levels of 17 β‐oes‐
tradiol (E2) in post‐menopausal women.
66 Treatment with E2 signifi‐
cantly reduces the risk of developing these pathologies67 because 
the action of E2 on ERs triggers the activation of intracellular signals 
that counteract the inflammatory process.68 However, these thera‐
peutic benefits provided by E2 can be accompanied by negative side 
effects, such as reproductive endocrine toxicity69 and the develop‐
ment of breast cancer.70 As a result of the above‐mentioned side 
effects, the administration of oestrogen in post‐menopausal women 
is not free from controversy and alternative compounds, such as ti‐
bolone, are being used in clinical practice (see further below).
3  | LIPOTOXICITY,  GLIAL CELLS , 
NEURODEGENERATION AND 
NEUROINFLAMMATION
The release and presence of a large amount of saturated FAs in 
the bloodstream can affect brain function. The development of 
inflammatory processes in the nervous system represents a deci‐
sive risk factor for neurodegenerative diseases. These changes in 
the cerebral environment contribute to the activation of microglia 
as a mechanism of defence and repair; however, the presence of 
exacerbated and prolonged processes can trigger a deregulation 
in microglial activation, which will stimulate additional release of 
inflammatory factors by these cells. This can culminate in the ele‐
vated levels of several pro‐inflammatory cytokines and the induc‐
tion of a chronic neuroinflammatory environment, a situation that 
is associated with many neurodegenerative disorders, such as age‐
related macular degeneration, AD, multiple sclerosis, Parkinson's 
disease (PD), Huntington's disease and tauopathies.71
The increase in life expectancy in some countries is directly 
related to the increase in the prevalence of AD.72 AD is mainly 
associated with ageing, with this being the main risk factor in the 
onset of this neurodegenerative pathology,73 although a higher 
risk has also been found in patients with obesity. Together with 
alterations in oxidative stress and mitochondrial dysfunction,74 
the progression of AD is directly linked to alterations in local im‐
mune responses, characterised by inflammation and activation of 
astrocytes and microglia.75 Indeed, neuroinflammation is involved 
in multiple pathological mechanisms of AD, and pro‐inflammatory 
mediators such as IL‐1β, IL‐6 and TNFα have been shown to be 
associated with the disease.76
Chronic inflammation in AD is a general observation,77 
whereas oxidative stress precedes neuronal damage.78 Other in‐
flammatory mediators such as IL‐1β, transforming growth factor‐β 
and inducible cyclo‐oxygenase‐2 have been found to be up‐reg‐
ulated in AD.76 Most studies and experimental evidence indicate 
that a pro‐inflammatory environment promotes the develop‐
ment of AD, whereas anti‐inflammatory treatment decreases its 
progression.79,80
Neuroinflammation may be neuroprotective at early stages 
but has chronic negative effects if the stimulus responsible for in‐
flammation persists, causing over‐activation of microglia and the 
increased release of cytokines.81 For example, amyloid plaques 
are surrounded by glia that secrete pro‐inflammatory molecules, 
including TNFα, IL‐1β and monocyte chemoattractant protein 
(MCP)‐1, which in turn increase neuronal sensitivity to free rad‐
icals and accelerate neurodegeneration.82 Another factor that 
favours neuroinflammation is inducible nitric oxide synthase, 
which has been found to be increased in the AD brains.83 The ef‐
fects of treatment with non‐steroidal anti‐inflammatory drugs84 
and oestrogens on the inflammatory processes involved in dif‐
ferent diseases have been widely reported.85 As a result of the 
low oestrogen levels that have been found in obese patients with 
increased levels of free FAs, hormonal supplements have been 
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used33,40 and this replacement therapy significantly decreased the 
risk of developing the disease47 (Figure 2).
PD is another neurodegenerative disease affected by the neu‐
roinflammatory processes activated by FAs, representing the sec‐
ond most common neurodegenerative disorder after AD. It affects 
1%‐2% of the general population aged ober 65 years of age.86 One 
of the markers of neurodegeneration in PD is the abnormal accumu‐
lation of α‐synuclein protein in neurones, which triggers the acti‐
vation of glial cells and the progression of inflammation.87 Reactive 
microglia have been observed in the substantia nigra of patients with 
PD, which suggests that this inflammatory process could aggravate 
neurodegeneration.88 Indeed, active microglia and, to a lesser ex‐
tent, reactive astrocytes are associated with neuronal loss. This is a 
result of the release of TNFα, IL‐1β and IL‐6, prostaglandins (PGE2, 
PGD2), ROS and nitric oxide (NO).89 However, analysis of neuronal 
loss in patients with PD demonstrates that it is a heterogeneous pro‐
cess because neurones containing neuromelanin are predominantly 
involved.90 This leads to an increase in the pro‐inflammatory mole‐
cules TNFα, IL‐6 and NO that trigger neuroinflammatory processes. 
It is noteworthy that neuromelanin has a crucial role in microglial 
activation, which leads to a vicious circle of neuronal death.91
4  | OESTROGENS AND THE BRAIN
Oestrogens play a vital role in both male and female reproductive 
physiology, stimulating cell growth and differentiation in various 
tissues such as breast, uterus, vagina, ovary, testis, epididymis and 
prostate.92 It has been shown that oestrogens are of great impor‐
tance in cardiovascular physiology; for example, the risk of cardio‐
vascular disease is lower in women than in men before menopause.93 
After menopause, the level of E2, the oestrogen that predominates 
in the circulation before menopause, decreases to the level found in 
men of similar age and can sometimes be even lower.94 Oestrogens 
are required for neuronal growth and differentiation and are known 
to affect cognitive and mood functions. In addition, oestrogens 
can be useful in preventing or delaying the onset of degenerative 
diseases of the nervous system. Most actions of oestrogens in the 
F I G U R E  2   Effect of fatty acids (FA) on the central nervous system. Metabolic diseases such as obesity are characterised by the 
accumulation of multiple metabolites that generate alterations on physiological conditions. The excess of fatty acids can contribute to an 
increase in inflammatory processes directly affecting the brain. The increase in the blood brain‐barrier (BBB) permeability facilitates the 
entry of FA and subsequent recognition by brain cells (neurones, astrocytes, microglia), triggering different response mechanisms that 
contribute to the appearance of a neuroinflammatory environment, as characterised by secretion of inflammatory cytokines, the activation 
of glial cells and neuronal death, amongst others. The activation of microglia implies morphological and functional changes from a chronic 
inflammation, by which signalling pathways and transcription factors related to apoptotic processes and cell death contribute to the risk of 
developing neurodegenerative diseases. ER, endoplasmic reticulum; IGF, insulin‐like growth factor; IL, interleukin, ROS, reactive oxygen 
species; TNF, tumour necrosis factor
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brain are considered to be mediated by activation of ERα, ERβ or 
G protein‐coupled receptor for oestrogen (GPER), and this topic is 
discussed below.
4.1 | Role of oestrogenic compounds in glial cell 
function and inflammation
ERs are proteins belonging to the superfamily of nuclear receptors, 
which also include other receptors for steroid hormones, the vitamin 
D receptor, retinoids, thyroid hormone and some orphan receptors. 
ERs were identified approximately 40 years ago when, in 1962, the 
presence of oestrogen‐binding sites in different tissues of rats was 
described. Two isoforms are currently known: ERα and ERβ.95 The 
ERs present a diverse subcellular localisation and can be detected 
in the cytoplasm,96 nucleus,97 mitochondria and endoplasmic retic‐
ulum.98 Both receptors (ERα and ERβ) have different functions ac‐
cording to the tissue where they exert their actions. The classical 
theory of action of steroid hormones states that the steroid receptor 
is activated by binding to the ligand (in this case E2) and acts as a 
transcription factor by binding to DNA and stimulating gene tran‐
scription. Because these nuclear receptors exert their actions in the 
nucleus, their mode of action is so termed genomic.99 The transcrip‐
tion stimulated by the ER is regulated in a tissue‐specific manner. 
However, in addition to its canonical response, oestradiol can induce 
effects quickly and independently of genomic mechanisms.100 The 
non‐genomic mode of action of oestradiol (and in general for all 
steroid hormones) is a rapid process that does not require the syn‐
thesis of new proteins, and is mediated by receptors localised in the 
membrane.101 The rapid oestrogenic action includes the regulation 
of ion fluxes, discharge of secretory vesicles and activation of pro‐
tein kinases associated with the membrane.102 In 1967, the idea that 
oestradiol could induce its cellular effects via non‐genomic mecha‐
nisms was introduced, as indicated by the increase in the production 
of cyclic AMP (cAMP) in vivo.103,104 Subsequently, it was demon‐
strated that E2 increases the intracellular concentration of Ca
2+ in‐
duced by glucose and cyclic GMP in beta cells of the pancreas.105
In the last decade, evidence has emerged concerning the role 
of GPER in the metabolic regulation of the nervous system.106 The 
GPER is a receptor coupled to the G protein of seven transmem‐
brane domains, whereas its expression and distribution have been 
demonstrated in a wide variety of cells and tissues.107 The GPER is 
located in the plasma membrane, although many investigations have 
identified it in other subcellular compartments, particularly in the 
endoplasmic reticulum and the Golgi apparatus,108 suggesting possi‐
ble role of oestrogen in these organelles.
It has been shown that oestradiol binds to the GPER and acti‐
vates multiple signalling pathways.107 It is known that GPER exerts 
its effects via rapid non‐genomic signalling and transcriptional ac‐
tivation.109,110 The mechanisms of action of this receptor depend 
on the type of tissue, as well as the abundance and expression of 
receptors. The rapid non‐genomic signalling in response to E2 via 
GPER can activate multiple signalling pathways, including mitogen‐
activated protein kinase, phosphoinositide 3‐kinase, protein kinase 
C, Ca2+ and adenylyl cyclase,111‐113 demonstrating the activation of 
some survival and metabolic downstream pathways. Depending on 
the cellular context, the GPER can mediate proliferative and survival 
responses.114 Although the mechanisms of action of the GPER are 
still unclear, it has also been described as a target of other molecules 
with oestrogenic activity, such as tamoxifen, which has been related 
to the regulation of functions in the central nervous system.115
There is a key regulatory role of the oestrogenic response in 
inflammatory processes.116,117 In inflammatory in vitro and in vivo 
models, it has been shown that administration of oestradiol and 
selective ER modulators (SERMs) decreases the expression of the 
pro‐inflammatory cytokines IL‐1β, IL‐10 and TNFα.118,119 Raloxifene, 
another SERM, has also been shown to protect mitochondria in as‐
trocytic cells exposed to glucose deprivation.120 By contrast, admin‐
istration of oestradiol can modulate the mitogenic stimulation of B 
and T lymphocytes and, as a consequence, increase the production 
of immunoglobulins such as immunoglobulin M. Indeed, epidemio‐
logical studies have shown that women of any age experience lower 
rates of infection and mortality associated with inflammatory pro‐
cesses compared to men.121
The relationship between the oestrogenic response and in‐
flammation is also associated with the differential activity of the 
ER subtypes.122 For example, in patients with rheumatoid arthri‐
tis, a density analysis of ERα and ERβ in synoviocytes showed a 
greater presence of ERβ.121 The same trend is observed in patients 
with systemic lupus erythematosus, where T lymphocytes have 
a higher concentration of ERβ+ lymphocytes than ERα+ lympho‐
cytes.122 In the case of the nervous system, inflammation can 
be triggered by conditions such as oxidative stress, endotoxins, 
mechanical damage and chronic neurodegenerative diseases.123 
Inflammation can be acute or chronic and the oestrogenic re‐
sponse can influence or modulate the two types of response, 
which can involve cellular components such as microglia and as‐
trocytes.124‐126 It has been shown that human astrocytes can se‐
crete molecules associated with inflammation such as interleukins, 
as well as chemotactic factors such as MCP‐1, macrophage inflam‐
matory protein‐1α and interferon‐γ‐inducible protein 10.127 It was 
reported that astrocytes are actively involved in the secretion of 
pro‐inflammatory molecules IL‐6 and interferon (INF)γ.116,128,129 
Additionally, oestradiol has the ability to decrease the secretion 
of these inflammatory molecules in an oxidative model mediated 
by H2O2 following stimulation with lipopolysaccharide (LPS), for 
which the response is associated with the NF‐κB pathway.130 This 
response is similar in astrocytes as a result of a reduction in the 
release of pro‐inflammatory molecules in metabolic dysfunction 
models,131 such as stimulation with palmitic acid27 (Figure 3).
Some neurosteroids such as dehydroepiandrosterone modu‐
late microglial activation and the immune response in vitro.132 In in 
vivo experiments, neuroactive steroids inhibited TNFα and INFγ in 
astrocytes and microglia.133 By contrast, progesterone did not in‐
hibit the immune responses of microglia85 but prevented morpho‐
logical changes associated with activated microglia phenotype.134 
Additionally, other studies reported that progesterone did not have 
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anti‐inflammatory effects on mixed cultures of astrocytes and mi‐
croglia but inhibited microglial proliferation in separate cultures.135
Both central and peripheral steroids participate in the activation 
and protection of the brain, in particular during the aging process 
and after an injury.136 The neuroprotective actions of steroids have 
been reported in several studies, in which it was shown that these 
compounds have a highly specific affinity to their nuclear receptors 
and mediate several protective functions, among which are the in‐
crease in the levels of anti‐inflammatory factors and anti‐apoptotic 
factors, as well as a decrease in the expression of inflammatory me‐
diators.137 Pregnenolone and dehydroepiandrosterone are known 
to promote the survival and differentiation of neuronal cells grown 
from embryonic rat brain.138 In a similar way, oestradiol, tamoxifen 
and raloxifene reduced the activation of microglia in male and female 
rats after peripheral inflammation induced by the administration of 
LPS. This latter effect was proposed to be mediated by a mechanism 
that may involve ER in microglia, thereby improving cell survival de‐
pending on the sex.139
The classical mechanism of action of steroid hormones in the 
brain is via interaction with their intracellular receptors (ERs, 
progesterone and androgen receptors).140,141 The expression of 
these receptors by glial cells allows them to partially mediate the 
action of oestrogenic compounds in the brain.118 Indeed, the re‐
sponse induced by each receptor stimulates cell survival, differ‐
entiation and connectivity of neurones and glial cells in the brain, 
including the medulla.102 Also, neurosteroids play an important 
role in the development of the prenatal CNS, at the same time 
as regulating behaviour and neuroendocrine signalling in the adult 
brain.142 Although many of the signalling pathways activated by 
oestrogen are known, the anti‐inflammatory molecular mecha‐
nisms are not completely clear.143
Many of the neurodegenerative diseases are characterised by 
the development of brain inflammation as a consequence of injuries 
or metabolic damage.59 As noted above, inflammation in the nervous 
system can be triggered by conditions such as oxidative stress, endo‐
toxins, cytokine secretion, mechanical injury and chronic neurode‐
generative pathologies.12 This inflammation can be acute or chronic, 
and the cellular components of the nervous system such as microglia 
or astroglia, can respond to oestrogenic activity by modulating these 
inflammatory processes.126
F I G U R E  3   Neurosteroids and neuroactive steroids have protective effects on the central nervous system cells. Treatment with 
oestradiol, selective oestrogen receptor modulators (SERMs) and selective tissue‐specific oestrogenic activity regulators (STEARs) has 
protective effects on the integrity of the cerebral microenvironment. Different investigations have reported that these molecules recover 
mitochondrial functions, oxidative stress, reduce the release of inflammatory factors (chemokines, cytokines, etc.) and attenuate the 
expression of proinflammatory and pro‐apoptotic proteins and genes. This protection is a result of the activation of oestrogen receptors and 
G protein‐coupled receptor for oestrogen (GPER), amongst others, where, via genomic and non‐genomic mechanisms, they activate the anti‐
inflammatory response and cell survival. ER, endoplasmic reticulum; IL, interleukin, ROS, reactive oxygen species
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Body weight increases in several conditions associated with hor‐
monal decline. In women, oestrogens favour the deposition of fat in 
some parts of the body; however, after menopause, the fat subcel‐
lular localisation changes, being more similar to men.144 The adipose 
tissue is capable of producing oestrogens via the aromatisation of 
androgens and an increase in the blood concentration of oestrogens 
has been observed in men with obesity, although this is not evident in 
women.145 It has been demonstrated that ERα is the main isoform that 
participates in the control of weight by oestrogens and the absence 
of ERα produces hyperplasia and hypertrophy of the adipocytes.146
Taking into account alterations in plasma oestrogen levels, an in‐
crease in free saturated FAs and the infiltration of pro‐inflammatory 
agents together present the ideal scenario for the development of 
neurodegenerative diseases. Oestrogens play a fundamental role 
in the prevention of obesity.147 Studies in female mice showed a 
weight gain and hyperadiposity after ovariectomy, which eliminates 
endogenous oestrogens. Interestingly, treatment with oestradiol re‐
duced the development of this obese phenotype,148 demonstrating 
that these effects on the homeostasis of body weight are mediated 
mainly by the activation of ER.149 Humans or mice with mutations in 
the ER gene (ESR1) are obese.150 Similalrly, oestradiol therapy was 
found to have no effect in mice subjected to ER suppression.151
The oestrogenic response associated with inflammatory pro‐
cesses has been found to have the ability to decrease the secretion 
of inflammatory molecules and reduce the production of ROS.152 In 
this regard, it was reported that this mechanism was associated with 
the response of ER via the activation of the inflammatory pathway 
NF‐κB,153,154 as well as the expression and modification of some 
proteins such as neuroglobin.24 For example, neuroglobin is a mo‐
nomeric globin protein of approximately 150 amino acids155 that has 
the capacity to transport and store oxygen as a result of the haem 
group that it contains.156 Hormonal regulation of neuroglobin and 
protective mechanisms are discussed in more details below.
4.2 | Signalling mechanisms associated with 
oestrogen‐induced neuroprotection
Neuroglobin has been studied in different models of damage such 
as focal cerebral ischaemia, β‐amyloid peptide‐mediated toxicity, 
anoxia, and glucose and oxygen deprivation.157 The presence of 
neuroglobin, once assumed to be expressed only in neurones, has 
recently been discovered in glial cells. Although the neuroprotec‐
tive effects of neuroglobin have been identified in these models, its 
molecular mechanisms of action are not yet well established.158,159 
Several investigations have found that oestrogens and androgens 
can regulate the expression of neuroglobin; hence, the modulation of 
this protein by oestrogenic activity160 could be partly responsible for 
the protective effects of oestradiol in models of oxidative stress.157
Despite its broad spectrum of protective effects, the molecular 
mechanisms of action of neuroglobin are poorly understood.161 It has 
recently been shown that neuroglobin is a hormone‐inducible pro‐
tein.162 Neuroglobin has the potential to be a hypoxia signalling mol‐
ecule, free radical scavenger or NADH oxidase capable of supporting 
anaerobic glycolysis.161 Several lines of evidence regarding tendency 
of neuroglobin to auto‐oxidate, as well as its low concentration in 
the brain (approximately 1 μmol L‐1) and its low affinity for oxygen, 
suggest that neuroglobin could play different roles ranging from ox‐
ygen storage to facilitating its diffusion.163,164 Additionally, photoac‐
tivation experiments of NADH/flavin mononucleotide that induce a 
reducing state in neuroglobin suggest that this protein participates 
in the elimination of oxygen radicals, mainly by reacting with NO to 
form a peroxynitrite radical that converts to the more stable form 
nitrite.165 The previous mechanism suggests a protective role for 
neuroglobin in the regulation of highly reactive species such as per‐
oxynitrite.166 Under conditions of normoxia, neuroglobin is bound to 
oxygen, whereas, under hypoxic conditions, and according to deoxy‐
genation experiments, neuroglobin adopts a hexacoordinated struc‐
ture.163,167 This structure can be a signal indicating the low levels of 
oxygen in the cellular environment, triggering events to protect the 
cell from death.116 Therefore, overexpression of neuroglobin could 
increase survival in conditions of low oxygen levels. Additionally, hy‐
poxia produces a pH decrease and this condition also favours the 
hexacoordinated conformation of neuroglobin.167,168 Interestingly, 
neuroglobin is a hormone‐regulated protein,24,32,130,160 suggesting 
that oestrogenic compounds (oestradiol and tibolone) or androgens 
(testosterone) can modulate its expression. The protective actions of 
tibolone are discussed below.
5  | TIBOLONE: A NEUROACTIVE STEROID 
AND REGULATOR OF OESTROGENIC 
ACTIVITY
The family of drugs acting as selective tissue‐specific oestrogenic 
activity regulators is termed STEAR.169 The most representative 
molecule of this family of drugs is tibolone.170 Tibolone is considered 
as a synthetic steroid with oestrogenic, progestogenic and andro‐
genic activity.171 Tibolone is prescribed for the treatment of climac‐
teric symptoms in post‐menopausal women.172
Tibolone has a 3‐keto‐δ5‐10 configuration, a 7α‐methyl substit‐
uent, and a 17α‐ethynyl group that per se cannot explain its com‐
bined effects in different tissues such as vagina, bones and brain.170 
Additionally, this compound mimics the activity of oestradiol neither 
via an aromatic ring, nor via the 3‐OH substituent, which is neces‐
sary to act as an agonist of ER.77 Its similar activity to oestradiol is 
probably a result of the hydroxyl groups and isomeric metabolites.
Tibolone is rapidly metabolised in the body to three different 
metabolites: (i) 3α‐ and (ii) 3β‐OH‐tibolone, metabolised by the en‐
zymes 3α/β hydroxy‐steroid dehydrogenase (HSD), respectively, and 
(iii) δ4‐tibolone also called δ4‐isomer, metabolised by the enzyme 
3β‐HSD‐isomerase,77 which together explain the combined activity 
of tibolone. Specifically, clinical evidence has indicated that 3α‐ and 
3β‐OH‐tibolone metabolites are responsible for the oestrogenic 
activity, whereas δ4‐tibolone is associated with the progestogenic 
and androgenic activity, as determined by its ability to interact 
with androgen and progesterone receptors.169 Similar to one of the 
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predominant forms of oestrogen (oestradiol), tibolone is metabo‐
lised to weak sulphated oestrogenic forms that serve as a substrate 
of sulphatase‐type enzymes for the permanent production of oes‐
trogenic metabolites in different tissues.173
Tibolone and its metabolites have different types of activities 
(progestogenic, androgenic and oestrogenic) in different tissue 
types (liver, bone, breast tissue and brain, amongst others), depend‐
ing on the selective modulation of the receptors with which they 
interact.174 In studies where an oestrogenic compound (E2) was used 
in models of cerebral ischaemia in mice, it was demonstrated that 
the activation of the ERβ is neuroprotective against the damage.175 
Similarly, another study investigated the neuroprotective effects of 
oestradiol and an ERα ligand using a model of multiple sclerosis. In 
the absence of anti‐inflammatory effects, it was found that treat‐
ments based on the ERβ would potentially allow the development 
of neuroprotective strategies for different neurodegenerative dis‐
eases, whereas the use of ERα ligands should be restricted because 
of side effects in the womb and uterus.176 By contrast, other studies 
reported neuroprotection mediated by the ERα via signalling mecha‐
nisms mediated exclusively by astrocytes.177
In addition to oestrogenic compounds, progestogens and an‐
drogens have been studied in animal models for neurodegener‐
ative diseases, indicating their neuroprotective potential. In the 
case of progestogens, it has been reported that their synthesis can 
be induced by oestradiol in astrocytes,178 suggesting not only the 
importance of oestradiol on progesterone synthesis, but also their 
combined action with other steroids. The progestogenic activity 
of tibolone is of great interest given that protective effects medi‐
ated by progesterone (pre‐ and post‐insult) have been reported in 
different models that mimic the physiopathological conditions of 
important neurodegenerative diseases, such as oxidative insults 
by glutamate cytotoxicity and glucose deprivation, amongst oth‐
ers.179 In the CNS, different brain areas such as the hippocampus, 
cerebral cortex, spinal cord and sciatic nerve exhibit this protec‐
tive effect of tibolone180 (Table 1).
Interestingly, the actions of tibolone in the brain are partly 
mediated by ERβ. Tibolone has been shown to induce protective 
effects in both microglia and astroglial cells upon different inflam‐
matory stimuli.23,24,29‐32 For example, astrocytic cells exposed 
to glucose deprivation present more fragmented nuclei and in‐
creased levels of oxidative stress. Treatment of cells with tibolone 
(10 nmol L‐1) or diarylpropionitrile (an ERβ agonist) but not with 
propylpyrazole‐triol (an ERα agonist) preserved mitochondrial 
function and improved the outcome in a similar fashion,24 sug‐
gesting an oestrogenic action of tibolone in astrocytes. However, 
after blocking ERβ using an antagonist, protection with tibolone 
in astrocytic cells deprived of glucose is dampened and more cell 
death is observed.24 Similarly, in BV‐2 microglial cells exposed to 
lipotoxicity with palmitic acid, cells treated with tibolone are res‐
cued by a mechanism that involves ERβ and neuroglobin. In this 
TA B L E  1   Studies on the relationship between fatty acids and oestrogen in the brain
Reference In vitro/in vivo model Aims Results
16 Microglial cell line BV‐2 and 
primary microglia
Effect of palmitic acid and stearic acid on mi‐
croglial activation and their relationship with 
Alzheimer's disease
Palmitic acid activated microglia and stimulated 
the TLR4/NF‐κB pathway promoting the pro‐
duction of proinflammatory mediators
27 Primary astrocytes derived 
from male and female 
Wistar rat hippocampus
Effects of oestradiol in astrocytes exposed 
to palmitic acid, with important sex‐related 
outcomes
Palmitic acid increased the ER stress and 
induced cell death. Oestradiol increased the 
levels of protective factors in astrocytes of 
both sexes, with a clear sex dimorphic response
31 T98G human astrocytic Effect of tibolone on mitochondrial function in 
human astrocytes exposed to palmitic acid
Tibolone improved cell survival and preserved 
mitochondrial membrane potential in astrocytic 
cells treated with palmitic acid.
10 Mouse BV‐2 microglia 
cells, exposed to LPS and 
palmitic acid
Effects of free fatty acids on the microglial 
response to inflammatory stimuli
Palmitic acid induced the alternative activation 
of microglia cells, affected the mRNA levels 
of the proinflammatory cytokines Ia‐1β and 
interleukin‐6
181 Human neuroblastoma 
cells SH‐SY5Y and human 
glioblastoma cells T98G
Neuroinflammation and reactive gliosis are as‐
sociated with the elevation of saturated fatty 
acids related to the high‐fat diet
Palmitic acid induced apoptosis by increasing 
oxidative stress in neurones and astrocytes
182 Ovariectomised C57BL/6 
female mice subjected 
to brain injury with sub‐
sequent treatment with 
tibolone
Evaluated the effect of tibolone on reactive 
gliosis in the cerebral cortex after brain injury 
in ovariectomised adult female mice
Tibolone exerted beneficial homeostatic actions 
in the cerebral cortex after acute brain injury
183 High‐fat diets in hypotha‐
lamic neurones and as‐
trocytes of male C57BL/6 
mice
Demonstrate that hypothalamic PGC‐1α regu‐
lates ERα and inflammation in vivo
PGC‐1α depletion with ERα overexpression 
significantly inhibited palmitic acid‐induced 
inflammation, confirming that ERα is a critical 
determinant of the anti‐inflammatory response
ER, oestrogen receptor; NF‐κB, nuclear factor‐kappa B; TLR, Toll‐like receptor.
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regard, several studies have shown that neuroglobin expression is 
increased in both astrocytes and microglial cells after treatment 
with oestradiol, testosterone and tibolone, suggesting that this 
protein is hormonally regulated. Blocking the expression of neuro‐
globin using small interfering RNA reduced the protective effects 
of tibolone in microglia and astrocytes subjected to metabolic dys‐
function.24,32 It has also been shown that tibolone induces protec‐
tion in glial cells by epigenetic mechanisms, and these include the 
regulation of IL‐6, microRNA, telomerase reverse transcriptase, 
DNA methylation and telomeric complex.29,30
6  | CONCLUSIONS
The excess of free saturated FAs in the circulation has direct ef‐
fects on the homeostasis and the functioning of the CNS. Free 
saturated FAs have consequences on different cells of the brain and 
their compartments. The main effects are demonstrated at the mi‐
tochondrial level, where an increase in oxidative stress contributes 
to the activation of inflammatory mechanisms that could lead to 
cell death. In the last decade, and as shown in this review, treat‐
ment with neuroactive steroids has been of great interest because 
of the fundamental protective role that they have on the CNS. 
Neuroactive steroids can be characterised by their anti‐oxidant and 
anti‐apoptotic properties, as well as their capacity to decrease glial 
activity. These protective effects on the survival and modulation 
of astrocytes and microglia are both dependent on and independ‐
ent of the ERs, which trigger the activation of signalling pathways 
and the transcription factors of genes involved in the inflammatory 
response and cell protection. Therefore, neuroactive steroids such 
as tibolone and oestradiol are promising therapeutic candidates 
for the treatment of pathologies that affect the CNS with respect 
attenuating the progression of diseases related to exacerbated in‐
flammatory processes. Future clinical studies on the use of steroids 
in the CNS diseases are warranted.
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